[Therapy of chronic inflammatory bowel diseases].
The standard therapy in Crohn's disease and ulcerative colitis is based on corticosteroids and aminosalicylates. Chronic active as well as fulminant disease usually require immunosuppressive therapy. The new biological have mostly disappointed because of lacking efficacy (Il-10, IL-11 or others) or serious adverse events (infliximab).
Stange
E F
EF
Abteilung für Innere Medizin 1, Robert-Bosch-Krankenhaus Stuttgart.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002908:Chronic Disease; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D016903:Drug Monitoring; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D012008:Recurrence; D012074:Remission Induction
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab; D001241:Aspirin